Generated by AI
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease. Its current pipeline is built around rademikibart, a monoclonal antibody aimed at interleukin-4 receptor alpha, as well as other research efforts in T cell-driven inflammatory disorders. Connect Biopharma works across respiratory and broader inflammation-related markets, reflecting a focus on diseases where immune signaling plays a central role. Headquartered in San Diego, California, Connect Biopharma Holdings Limited is positioned as a specialist developer of novel biologic treatments within the biotechnology sector.
Website3580 Carmel Mountain Road
San Diego, CA, 92130
United States
The latest articles about CNTB.
Connect Biopharma Holdings is back in focus after analysts refreshed their price targets, with fair value moving from US$5.88 to US$6.00 in the latest models. The shift follows new Street research that weighs the mixed Phase 2 Seabreeze STAT trial readout, updated Phase III timelines, and a balance of optimism around the asthma pipeline against execution and clinical risk. Read on to see how these revised targets fit into the evolving Connect Biopharma Holdings story and what to watch as the...
Summary of Nov 17's posts. Generated by AI.
Summary of Oct 1's posts. Generated by AI.
Summary of Sep 30's posts. Generated by AI.
Summary of Oct 2's posts. Generated by AI.
Investors talking about CNTB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.